Renagel is growing significantly around the world foundation in the United States, Europe, and Japan. With more than 1.2 million people around the globe undergoing need and the prospects are both substantial.

Genzyme took a major step to expand access to Renagel in September 2004, when we launched the Renagel REACH Program, driven by our commitment to treating as many patients as possible. A partnership with major providers of Medicare-approved drug discount cards, the initiative enables Medicare beneficiaries to receive Renagel at substantial income-based discounts.